《新股消息》君聖泰醫藥-B(02511.HK)今起招股 一手入場費5,808元
君聖泰醫藥-B(02511.HK)公布招股詳情,擬全球發售2,419.4萬股,香港公開發售佔一成,國際發售佔九成。每股招股價為11.5元。每手500股計,一手入場費為5,807.99元。該股今日(14日)起招股,下周二(19日)中午截止,預期下周五(22日)掛牌。聯席保薦人為瑞銀及華泰國際。
君聖泰醫藥為一間生物製藥公司,專注於就代謝及消化系統疾病的治療發現、開發及商業化多功能及多靶點療法。是次上市引入滄州創融為基石投資者,認購1.1億元公司股份。
公司上市料淨集資約1.94億元,當中約80%將用於為核心產品HTD1801的持續臨床研發活動提供資金;約5%用於為肥胖症的HTD1804的持續研發(包括研發人員成本及第三方合約開支)提供資金;約10%用於透過持續升級及加強FUSIONTXTM開發方式進行其他候選藥物的早期藥物發現及開發;約5%用作營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.